

39. (Amended) A method as in claim 60, wherein mizoribine is released at a rate between 10 µg/day to 60 µg/day.

40. (Amended) A method as in claim 60, wherein mizoribine is released within a time period of 1 day to 45 days in a vascular environment.

41. (Amended) A method as in claim 60, wherein mizoribine is released within a time period of 7 days to 21 days in a vascular environment.

42. (Amended) A method as in claim 60, further comprising releasing at least one other substance in addition to mizoribine simultaneously with mizoribine release.

43. (Amended) A method as in claim 60, further comprising releasing at least one other substance in addition to mizoribine sequentially with mizoribine release.

45. (Amended) A method as in claim 60, wherein the releasing comprises delaying substantial release of mizoribine for at least one hour following implantation of the prosthesis.

46. (Amended) A method as in claim 45, wherein delaying release comprises slowing releasing mizoribine from a reservoir with a material that at least partially degrades in a vascular environment over said one hour.

47. (Amended) A method as in claim 45, wherein delaying release comprises slowing releasing mizoribine with a matrix that at least partially degrades in a vascular environment over said one hour.

48. (Amended) A method as in claim 45, wherein delaying release comprises slowing releasing mizoribine with a nondegradable matrix that allows diffusion of mizoribine through the nondegradable matrix after said one hour.

49. (Amended) A method as in claim 45, wherein delaying release comprises slowing releasing mizoribine with a rate limiting barrier that allows diffusion of mizoribine through the barrier after said one hour.

51. (Amended) A method as in claim 60, wherein the prosthesis incorporates mizoribine by coating, spraying, dipping, deposition, chemical bonding, or painting mizoribine on the prosthesis.

60. (New) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:
implanting a vascular prosthesis in the blood vessel; and
releasing methylprednisolone from the prosthesis into the blood vessel so as to inhibit smooth muscle cell proliferation.